EUVIMEDEUVIMED entdecken
Crossref

Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma

Tian Wang iD, Chuang Huang, Jie Wang, Tianci Tang, Qiang Li, Yi Li, Xinmao Song iD

The Laryngoscope · 2025

DOI: 10.1002/lary.31968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Tian Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Rhabdomyosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Natural Science Foundation grants of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s) Head and neck rhabdomyosarcoma (HNRMS) is a rare malignant tumor in adults. No standard treatment for adults with HNRMS currently exists.

Methods

A retrospective study of 72 newly diagnosed consecutive adult patients with HNRMS was conducted at one institution between November 2010 and April 2023. The log‐rank tests were used to compare the differences in survival between treatment groups, and overall survival (OS), local recurrence‐free survival (LRFS), progression‐free survival (PFS), and distant metastasis‐free survival (DMFS) were calculated using the Kaplan–Meier method. We used restricted cubic spline models fitted for Cox proportional hazards models to determine the association between chemotherapy cycles/radiotherapy dose and mortality.

Results

The 2‐year OS, PFS, LRFS, and DMFS rates for the entire cohort were 51.0%, 39.2%, 44.3%, and 47.3%, respectively. Radiotherapy significantly improved the OS ( p < 0.01), PFS ( p < 0.01), LRFS ( p < 0.01), and DMFS ( p < 0.01). Surgery had no effect on OS (49.3% vs. 53.0%, p = 0.62), PFS (36.9% vs. 41.8%, p = 0.31), LRFS (41.6% vs. 47.4%, p = 0.27), or DMFS (44.4% vs. 50.2%, p = 0.43). The restricted cubic spline showed that eight (HR = 1.002, 95% CI: 0.996–1.007) cycles of chemotherapy and 62.5Gy radiation therapy resulted in the lowest mortality.

Conclusion

For HNRMS, eight cycles of chemotherapy and 62.5Gy of radiation might be sufficient. Poor response to chemotherapy predicted an extreme worse outcome. Surgery played a limited role in the treatment. Level of Evidence 3 Laryngoscope , 135:2022–2029, 2025

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsRhabdomyosarcomaHumansMaleRetrospective StudiesFemaleMiddle AgedAdultCombined Modality TherapyAgedTreatment OutcomeYoung AdultAdolescentSurvival Rate

Stichwörter der Autor:innen

adult head and neck rhabdomyosarcomachemotherapyradiotherapysurgerytreatment

Autor:innen und Institutionen

  • Department of Radiation Oncology, Eye, Ear, Nose & Throat Hospital of Fudan University, Shanghai, China.
  • Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
  • Chongqing University Cancer Hospital and Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China.
  • Department of Otorhinolaryngology, Jinshan Hospital Affiliated to Fudan University, Shanghai, China.
  • Department of Oncology, 920th Hospital of Joint Logistics Support Force, Kunming, China.

ORCID-Profile: Tian Wang, Xinmao Song

Förderung

  • Natural Science Foundation grants of Chongqing

Zitieren

APA

Wang, T., Huang, C., Wang, J., Tang, T., Li, Q., Li, Y., & Song, X. (2025). Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma. The Laryngoscope. https://doi.org/10.1002/lary.31968

Vancouver

Wang T, Huang C, Wang J, Tang T, Li Q, Li Y, et al. Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma. The Laryngoscope. 2025. doi:10.1002/lary.31968

BibTeX
@article{Wang2025,
  author = {Wang, Tian and Huang, Chuang and Wang, Jie and Tang, Tianci and Li, Qiang and Li, Yi and Song, Xinmao},
  title = {Multimodality Treatment Outcome in Adult Patients with Head and Neck Rhabdomyosarcoma},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.31968}
}
Kostenlos starten →